Current understanding of the impact of lipids and other risk factors on coronary heart disease is largely based on the results of parametric multiple regression analyses of large prospective studies. To assess the potential impact of the a priori assumption of linearity of continuous risk factors on the results of parametric analyses, the authors completed a secondary analysis of the Lipid Research Clinics Prevalence and Follow-up Studies (1972 data using an assumption-free nonparametric modeling approach. The effects of total serum cholesterol and the ratio of total serum cholesterol to high density lipoprotein cholesterol, adjusted for common risk factors, were estimated using a smoothing spline method available in the generalized additive model extension of the multiple logistic regression. The data set included 2,512 men in the random sample of the Lipid Research Clinics study who did not take lipid-lowering medications. During the median follow-up of 12.6 years, 94 coronary heart disease deaths occurred. The generalized additive model fits the effects of total serum cholesterol (p < 0.01) and the ratio of total serum cholesterol to high density lipoprotein cholesterol (p < 0.02) significantly better than the parametric logistic regression. Validation studies confirmed that, among new observations arising from the same population, generalized additive model estimates predicted outcomes better than the parametric estimates. Nonlinear effects of both lipid measures were robust and may be clinically important. The authors conclude that the linearity assumption inherent in parametric models may result in biased estimates of the effects of total serum cholesterol on coronary heart disease mortality and recommend that their findings be verified in a nonparametric analysis of data from another large prospective study. Am J Epidemiol 1997;145:714-29. coronary disease; lipids; models, statistical; risk factors Coronary heart disease (CHD) is a major cause of mortality and morbidity in Western societies. Accordingly, designing effective strategies for preventing CHD is among the highest priorities of public health officials. Serum cholesterol is recognized as a major CHD risk factor (1). Several interventions and clinical practice guidelines have been developed to reduce the incidence of CHD by changing the levels of modifi- able risk factors, and of serum cholesterol in particular (2-4). In the era of shrinking resources, the assessment of effectiveness and cost-effectiveness of the proposed prevention strategies has also received considerable attention (5-8).
Current understanding of the impact of lipids and other risk factors on coronary heart disease is largely based on the results of parametric multiple regression analyses of large prospective studies. To assess the potential impact of the a priori assumption of linearity of continuous risk factors on the results of parametric analyses, the authors completed a secondary analysis of the Lipid Research Clinics Prevalence and Follow-up Studies (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) ) data using an assumption-free nonparametric modeling approach. The effects of total serum cholesterol and the ratio of total serum cholesterol to high density lipoprotein cholesterol, adjusted for common risk factors, were estimated using a smoothing spline method available in the generalized additive model extension of the multiple logistic regression. The data set included 2,512 men in the random sample of the Lipid Research Clinics study who did not take lipid-lowering medications. During the median follow-up of 12.6 years, 94 coronary heart disease deaths occurred. The generalized additive model fits the effects of total serum cholesterol (p < 0.01) and the ratio of total serum cholesterol to high density lipoprotein cholesterol (p < 0.02) significantly better than the parametric logistic regression. Validation studies confirmed that, among new observations arising from the same population, generalized additive model estimates predicted outcomes better than the parametric estimates. Nonlinear effects of both lipid measures were robust and may be clinically important. The authors conclude that the linearity assumption inherent in parametric models may result in biased estimates of the effects of total serum cholesterol on coronary heart disease mortality and recommend that their findings be verified in a nonparametric analysis of data from another large prospective study. Am J Epidemiol 1997;145:714-29. coronary disease; lipids; models, statistical; risk factors Coronary heart disease (CHD) is a major cause of mortality and morbidity in Western societies. Accordingly, designing effective strategies for preventing CHD is among the highest priorities of public health officials. Serum cholesterol is recognized as a major CHD risk factor (1) . Several interventions and clinical practice guidelines have been developed to reduce the incidence of CHD by changing the levels of modifi-able risk factors, and of serum cholesterol in particular (2) (3) (4) . In the era of shrinking resources, the assessment of effectiveness and cost-effectiveness of the proposed prevention strategies has also received considerable attention (5) (6) (7) (8) .
Assessing the effect of an intervention based on risk factor modification involves comparing risks associated with different levels of the risk factor. Current perception of the effects of particular CHD risk factors relies strongly on large prospective epidemiologic studies such as the Framingham Heart Study (9) or the Multiple Risk Factor Intervention Trial (10) . In these studies, the outcomes of participants with different baseline values of risk factors are analyzed to estimate the relative and/or absolute risks associated with particular values. Statistical methods used to analyze results of prospective studies of CHD mortality/morbidity have evolved over time and have tracked, with some understandable delay, advancements in theoretical and applied statistics and the availability of software. While early analyses relied on univariate statistical methods, more recent ones typically use multiple logistic regression modeling to control for potential confounders and to estimate independent (adjusted) effects of particular risk factors (9) .
The multiple logistic regression model belongs to the broad family of parametric general linear models that rely on the assumption that the effects of continuous predictors are linear (linearity assumption). The linearity assumption simplifies both model estimation and interpretation of results since it allows for summarizing the effects of a continuous predictor by a single parameter (logarithm of odds ratio in the logistic model). However, the linearity assumption may be too simple to represent the effects of some risk factors correctly. Linearity dictates that the estimated change in the logit of risk due to changing the predictor value by a given amount is constant over the entire range of these values. For example, the linearity assumption requires that the estimated effect of lowering total serum cholesterol (TC) from 300 to 250 mg/dl on the logit of a CHD death is exactly the same as the effect of reducing TC from 200 to 150 mg/dl. It should be noted that this assumption is inconsistent with those analyses of CHD risks in which continuous risk factors have been categorized, implying a threshold effect (11) . More generally, it is possible that the risk increase may be steeper over, for example, the range of high TC values than over the range of moderate "normal" values. In such cases, the parametric logistic model will be incorrect and will result in biased estimates of relative and absolute risks. More specifically, if the linearity assumption is incorrect for a given risk factor, the parametric logistic regression estimate will underestimate its effect over some range of values and overestimate the effect over some other range.
In the last decade, a number of flexible nonparametric extensions of the conventional logistic regression model have been proposed in the statistical literature (12) (13) (14) (15) . These nonparametric regression methods eliminate the restrictive linearity assumption and allow greater flexibility in modeling the data so that the estimated effects of continuous risk factors may follow an arbitrary continuous smooth function. Accordingly, the risk of bias is largely reduced as the estimates depend more on empirical data and less on a priori assumptions. There are several reasons why flexible modeling of cholesterol effects is of interest First, the impact of CHD on mortality and morbidity makes it mandatory to provide as accurate as possible estimates of the effects of particular risk factors, even if it requires additional analytic and computational efforts. If statistically significant and clinically important departures from the linearity assumption are found, they may suggest the need to revise die current perception of the effectiveness and cost-effectiveness of various interventions aimed at the modification of risk factors.
On the other hand, if flexible nonparametric models yield estimates of the cholesterol effect that are very similar to those obtained from the parametric multiple logistic model, such results will enhance the scientific value of findings based on the latter model by providing a posteriori empiric validation of the underlying a priori assumptions.
In this study, we use a nonparametric regression approach to reassess the effects of selected continuous risk factors on the risk of CHD mortality, with particular focus on two lipid measures: TC and die ratio of TC to high density lipoprotein cholesterol (TC/HDL cholesterol).
MATERIALS AND METHODS

Data source
We completed a secondary analysis of the publicuse data provided by the Lipid Research Clinics (LRC) Program Prevalence and Follow-up Studies. Between 1972 and 1976, 10 North American clinics participated in the Prevalence Study aimed at estimating the prevalence of dyslipoproteinemias and related factors (16) (17) (18) . At the first visit, 60,502 individuals out of 81,926 initially contacted completed a questionnaire and had tiieir blood tested. A 15 percent "random sample" of the visit 1 participants as well as all individuals found to have abnormal lipid levels at visit 1 ("nonrandom sample") were then invited to return for visit 2, which took place on average 3 months later. The nonrandom sample included all participants taking lipid-lowering medication and those with TC and/or triglyceride values exceeding the respective age-and sex-specific cutoffs (19) . At visit 2, a complete medical history was taken, a physical examination was carried out, and TC and its fractions were measured. (Details of laboratory procedures can be found in references 16 and 18.) Participants were then followed prospectively until death or the end of the LRC Follow-up Study in June 1987 (20) . Participants or a reliable source were contacted to determine participants' vital status. Causes of mortality were established based on death certificates and hospital records (20) .
Our main analyses focus on male participants in the random sample. Individuals who were on lipid-lowering medications at visit 2 were eliminated from the data set. Following the argument presented by Benfante et al. (21) , their risks may be determined more by their (unknown) previous TC level than by the current level, likely to be reduced recently due to medication. The resulting data set includes 2,512 individuals widi the median follow-up time of 12.6 years (interquartile range, 1.2 years). Ninety-four CHD deaths occurred in this data set.
In some descriptive analyses and for the purpose of assessing the generalizability of our results, we use data on males in the nonrandom sample. After the exclusion of individuals on lipid-lowering medications as well as of an obvious outlier with the TC value above 1,000 mg/dl, there were 1,992 men in the nonrandom sample, among whom 102 died because of CHD.
Statistical analyses
Simple univariate statistics, t tests for continuous variables, and chi-square tests for binary variables were used to compare random and nonrandom samples. A significance level of a = 0.05 was used for all tests.
Main analyses relied on multivariable binary regression models with the outcome defined as a CHD death. Each multiple regression model included one of the two cholesterol measures, either TC or TC/HDL cholesterol, as well as a set of a priori selected risk factors: age, systolic blood pressure, body mass index (BMI), glucose intolerance, current smoking status, history of CHD, and the use of antihypertensive medication. All risk factors were represented by the values determined at visit 2. In the parametric multiple logistic regression model, the effect of each continuous risk factor on the logit of a CHD death was represented by a linear function.
Nonparametric modeling and testing of linearity. Generalized additive models (GAM) methodology (14, 15) was used for nonparametric modeling of the TC effects, adjusted for other risk factors. Cubic smoothing splines were used to estimate flexible functions that describe the dependence of the logit of a CHD death on the TC value. To test the significance of the nonlinear effects, we used the likelihood ratio test with the approximate chi-square statistics based on the effective number of degrees of freedom, corresponding to the trace of the smoother matrix (15) . The significant result of this test was interpreted as an evidence that the nonparametric smoothing spline estimate fits the data significantly better than the linear function estimated using the parametric logistic regression model. Simulations reported by Hastie and Tibshirani (15) show that, under the null hypothesis of a linear effect, the empiric distribution of the proposed likelihood ratio statistics in its upper tail is very similar to the theoretical chi-square distribution with the appropriate number of degrees of freedom. This means that the test of the nonparametric effect is reliable at the conventional significance levels a = 0.05 or a = 0.01. A parsimonious 2-df smoothing spline model was chosen a priori for the purpose of testing the significance of nonparametric effects. According to our expectations, this model should provide sufficient flexibility to ensure that the estimation of the risk function would be reasonably free of bias, while protecting against the risk of overfitting the data that is present with more complex models (22) . Basing significance testing on an a priori selected model also avoids the problem of inflation of type I error rate that occurs if the model is selected a posteriori (23, 24) .
In the above analyses, we rely on the GAM generalization of the binary regression model, which allows us to estimate absolute risks (probabilities of CHD death associated with different risk profiles; see Clinical relevance of nonlinear effects), in addition to relative risks. However, to evaluate the robustness of our conclusions about the shape of the estimated risk function and about the significance of nonparametric effects, our main analyses described in this subsection were replicated using the GAM generalization of the Cox proportional hazards model (15) . As in binary regression analyses, the effect of TC or TC/HDL cholesterol was represented by a 2-df smoothing spline and was adjusted for the same risk factors. Given the very high censoring level (above 95 percent) and little variation in the duration of follow-up in our data, we a priori expect that the results of the proportional hazards analyses will be very similar to those of the binary regression. Therefore, all further analyses, described in the following subsections, are limited to the binary regression approach.
Model selection. A posteriori model selection criteria may be useful for descriptive purposes since they allow us to determine which model provides an optimal trade-off between the fit to data and model parsimony. Therefore, we estimated GAM models with different degrees of freedom and used the Akaike Information Criterion (AIC) (25) as well as the Bayesian Information Criterion (BIC) (26) to find the bestfitting model, corresponding to the minimum of a given criterion value. While AIC is more commonly used, the BIC criterion has the advantage of accounting for the sample size and has been found to perform better in other nonparametric analyses (22, 23) .
In the preliminary GAM analyses, the nonparametric modeling was limited to the cholesterol effects. Final analyses were based on a more complex GAM model in which the effect of each continuous risk factor (age, systolic pressure, BMI, and TC or TC/ HDL cholesterol) was represented by a 2-df smoothing spline. We assessed also the sensitivity of the estimates with respect to the decision whether to include in the analysis the participants on antihypertension medications and/or those with a history of CHD. In additional exploratory analyses, we used different subsets of the original data set to investigate some post hoc suggestions as well as to illustrate some properties of the estimates derived from different models.
Model validation. Results of multivariable modeling of the data on men in the random sample were validated using two approaches based, respectively, on 1) independent data (nonrandom sample) and 2) crossvalidation of the random sample. In both approaches, we treated the random sample as a "learning sample" and used the resulting estimated regression coefficients to calculate the estimated probability of a CHD death for each subject in a "testing sample." Comparison of the estimated probabilities for individual subjects with the actual outcomes (CHD death or not) for the same subject yielded the log-likelihood of the data in the testing sample under the model estimated from the learning sample. The log-likelihood was used as a criterion to assess the goodness of fit of the estimated model to independent data.
The first approach consisted of using the nonrandom sample of men as the testing sample. In this part of the validation study, we attempted to assess to what extent the estimates obtained with the random sample of LRC data are generalizable to other similar data sets. Given that at present we do not have access to detailed data from a different, large, prospective CHD study, we have decided to use the nonrandom sample of the LRC study for this purpose. However, validation results based on the nonrandom sample should be interpreted with caution since this sample is composed of individuals selected specifically because they were perceived to be at a high risk of CHD events (19) . Therefore, the individuals in the nonrandom sample, in addition to having a different distribution of common risk factors recorded in the LRC study, may differ from the randomly selected individuals with respect to some more subtle clinical characteristics and/or other unrecorded variables associated with CHD risks.
The purpose of the second part of the validation study was to compare the reproducibility of the estimates obtained with different models in terms of their ability to predict outcomes in "new cases" arising from the same population. The approach consisted of a 10-fold cross-validation of the random sample estimates. The random sample was first randomly divided in 10 subsets of approximately equal size. Then, a learning sample was constructed as the sum of the nine subsets, and the tenth subset was used as a testing sample. The same process of estimation and validation was repeated nine additional times, each time using a different subset as a testing sample and nine other subsets as a learning sample. This procedure ensures that for each individual the outcome is predicted based on the model estimated independently of the individual's data (i.e., estimated from the nine subsets that do not include this individual). By summing up the loglikelihood values obtained in each of the 10 subsets, we calculated the cross-validated log likelihood of the entire random sample.
Clinical relevance of nonlinear effects. To assess the clinical importance of the differences between the parametric and the nonparametric estimates, we compared the results of the logistic regression and GAM analyses with respect to the estimated effects of some arbitrary changes in the TC level on the probability of a CHD death for hypothetical patients with prespecified risk profiles.
RESULTS
Baseline characteristics: random versus nonrandom sample Table 1 compares the distributions of risk factors among men in random and nonrandom subsets of LRC data. In most cases, the mean values of continuous risk factors and the prevalence of binary factors in the nonrandom sample are statistically significantly higher than the corresponding values in the random sample, except for HDL cholesterol, which is lower, as expected. Although the majority of the differences are not clinically important, for TC and TC/HDL cholesterol the mean values in the nonrandom sample are very substantially higher than in the random sample, which reflects the design of the LRC study (19) . Accordingly, the question of homogeneity of the lipid effects across random and nonrandom samples has to be investigated. Table 2 presents the results of the conventional multiple logistic regression analyses of CHD mortality in the two samples, with the effects of all continuous risk factors assumed to be linear in logit. All results are from the model that included TC but not TC/HDL cholesterol. The results for TC/HDL cholesterol are adjusted for all other risk factors except TC. (Results for other risk factors did not change materially when TC was replaced by TC/HDL cholesterol.) Interestingly, there is no evidence of the independent effect of BMI on the risk of CHD death in men since in both samples p values are very high and adjusted odds ratios are very close to 1.0. Post hoc analysis suggested that the unexpected nonsignificance of the adjusted effect of systolic pressure in the nonrandom sample was likely due to the near collinearity between systolic pressure and the use of antihypertensive medication in that sample. This problem did not occur in the random sample, where the adjusted effect of systolic pressure is highly significant. All other risk fac- tors are significant, and the corresponding odds ratios estimated from random and nonrandom samples are very similar for most risk factors. However, the estimated effect of TC/HDL cholesterol is weaker in the nonrandom sample. A one-unit increase in TC/HDL cholesterol corresponds to the estimated relative risk increase of 33 percent (95 percent confidence interval (CI) 19-48) and 14 percent (95 percent CI 5-23) in the random and nonrandom samples, respectively. Moreover, the two estimates of the intercept, corresponding to the estimated logit of a CHD death for a specific covariate pattern (all covariate values equal to zero), are quite different: -10.1 (95 percent CI -12.4 to -7.8) and -7.2 (95 percent CI -9.6 to -4.8) for the random and nonrandom samples, respectively. The fact that, for a fixed covariate pattern, the estimated risks are substantially higher in the nonrandom sample indicates that the higher mortality rate (table 2) in this sample is not completely accounted for by the differences in the distribution of common risk factors. This may suggest that the participants included in the nonrandom sample have some other high-risk characteristics not taken into consideration in our analyses.
Parametric logistic regression modeling
Nonparametric effects of lipids
In table 3, we present the results of separate nonparametric multivariable GAM analyses of the adjusted effects of TC and TC/HDL cholesterol for males in the random sample. The effect of each lipid variable is adjusted for all other risk factors listed in table 2, and all of the other risk factors are modeled parametrically. We focus first on the GAM models with 2 df since these parsimonious models were selected a priori to test the significance of the nonlinear effects of cholesterol. The p values for the likelihood ratio tests of the nonlinearity of the adjusted effect are below 0.05 for both TC (p < 0.01) and TC/HDL cholesterol (p < 0.02). This indicates that the 2-df smoothing spline estimates obtained from the GAM model represent the effects of cholesterol on CHD mortality significantly better than the linear estimates derived from the conventional logistic regression, p values for models with higher degrees of freedom confirm the significance of the nonlinear effects at a = 0.O5. However, the p values increase with the increasing model complexity, suggesting that additional degrees of freedom may be not necessary to model systematic effects of cholesterol. This is further corroborated by the model selection criteria. While the differences between the corresponding AIC values assigned to the three models are very small, the 2-df model is definitely superior with respect to a more adequate sample size-dependent BIC criterion (table 3) . In GAM, the estimated effect of a continuous risk factor is represented by a flexible function rather than by a single parameter (logarithm of odds ratio in the logistic model), so that the best way to appreciate the results is to plot this function. The left panel of figure  1 compares the parametric logistic regression-based estimate (dashed line) of the effect of TC on the logit of a CHD death with the corresponding estimates obtained from GAM models with different degrees of freedom. The tick marks on the abscissa illustrate the sample distribution of TC, indicating that the estimates are well supported by the data in the range between about 130 and 300 mg/dl. The upper tail of the graph is truncated because the very sparse data beyond 300 mg/dl produce unstable estimates in that region. All of the estimates are adjusted for the effects of nonlipid risk factors listed in table 1. Therefore, a given curve represents the estimated dependence of the logit of a CHD death on TC in a hypothetical population homogeneous with respect to age, systolic pressure, BMI, smoking status, previous history of CHD, and the presence/absence of diabetes. A priori assumptions underlying the parametric logistic regression model restrict this relation to a linear function, which implies that the slope has to be constant over the entire range of TC. The nonparametric GAM estimates are more flexible so that the estimated slope may change along that range. The GAM estimates are restricted only in that they have to exhibit some degree of smoothness that decreases with increasing complexity of the model (i.e., with increasing degrees of freedom). The higher the local slope over a given subinterval of abscissa, the higher the impact of changing TC value in this specific range.
All nonparametric GAM estimates describe a similar pattern of the effects of TC: Over the range of 100-250 mg/dl, the risks increase quickly and approximately linearly, whereas above the level of 250 mg/dl, the risk function levels off. Among GAM estimates, the 2-df estimate (solid curve) appears to be the most plausible one clinically. The 2-df smoothing spline estimate is monotonically nondecreasing. By contrast, the higher estimates of degrees of freedom suggest that the risk decreases substantially with increasing TC beyond the level of 250 mg/dl, which seems counterintuitive and may reflect sampling error rather than a systematic effect. Moreover, the monotone 2-df estimate is within the 95 percent confidence intervals for the more complex models (data not shown), which provides further support for the relatively parsimonious 2-df nonparametric model (27) . The 10-df estimate of the risk function exhibits several bumps and The graphs correspond to an arbitrary vector of rtonlipid risk factor values, so that the logrt scale on the vertical axis has a valid unit but an arbitrary zero. Accordingly, the relative risks between different risk factor values are accurately represented, but absolute risk levels should not be interpreted. CMD, coronary heart disease.
valleys and illustrates the overfitting bias inherent in models that are more complex than required to represent the relation of interest (22) . Given all the above remarks, the visual assessment of the estimates confirms that the BIC-optimal, 2-df model is unlikely to miss any systematic aspects of the effect of TC in the range from about 130 to 300 mg/dl, where most of our data fall. Obviously, the number of observations beyond this range is too low to allow stable estimation of this effect in the tails of TC distribution. A somewhat similar pattern of results emerges in the right panel of figure 1 , where the effects of TC/HDL cholesterol are presented. The estimated risk increases in a linear fashion over the range of values lower than 7.0, but increasing the TC/HDL cholesterol beyond this level has a less dramatic effect The analyses reported in this subsection were replicated using the GAM generalization of the Cox proportional hazards model, with the adjusted effects of TC or TC/HDL cholesterol represented by a 2-df smoothing spline. (Because of near collinearity of the estimated effects of the history of previous CHD and diabetes, only one of these two variables could be included in these additional analyses. The results obtained with either variable excluded were almost identical.) Consistent with our expectations, the results of the GAM proportional hazards modeling were very similar to those of the binary regression analyses reported above. The likelihood ratio tests indicated that the inclusion of the nonparametric effects of either TC or TC/HDL cholesterol significantly improved the fit of the models to data (at a = 0.05). Moreover, for either lipid measure, the estimated risk functions were very similar to the 2-df estimates presented in figure 1 . The conclusions regarding the shape and significance of the relevant effects did not change materially when the analyses were restricted to a subset of individuals without previous history of CHD (data not shown). Table 4 and figure 2 present the results of the analysis of the sensitivity of the conclusions regarding the nonlinear effects of cholesterol, represented by the 2-df smoothing spline estimates, with respect to changes in the data set. Table 4 indicates mat the significance of nonlinear effects persists when the sample size is reduced by eliminating high-risk subgroups (individuals on antihypertensive medication and/or those with the history of previous CHD). Moreover, all estimates in figure 2 are quite similar, which shows that the finding of a decreasing impact of TC on CHD mortality in the upper range of TC is robust with respect to the changes in the data set.
Robustness of nonlinear effects
Exploring the bias of linear estimates
Statistical significance and robustness of the nonlinear effects of cholesterol indicates that the conventional logistic regression-based analyses provide biased estimates of these effects. Comparison of the linear estimate with GAM-based spline estimates in figure 1 (left panel) shows that this bias is due to the inability of the linear model to account for the decreasing impact of TC above the level of 250 mg/dl. Therefore, for the LRC data, the conventional linear model seems to overestimate the effects of changing TC in the upper range of where the effect is nonlinear. The reason why the strength of association between TC and risks of CHD death decreases among individuals with TC values above 250 mg/dl is not evident and may be partly related to the limitations of the available data (see Discussion). By contrast, all nonparametric estimates of TC effects presented in figure 1 (left panel) look quite linear for TC values lower than 250 mg/dl, suggesting that the linearity assumption holds for this range of TC values. In spite of this, the logistic regression estimate is quite different from the GAM estimates, even for the range of values below 250 mg/dl. More specifically, the slope of the logistic regression estimate is much lower than the slopes of nonparametric estimates over this range.
To explore further why the two estimates diverge even over the interval where both are approximately linear, we reestimated the respective models using only data for those participants whose TC was below 250 mg/dl. In figure 3 , we compare the estimates obtained with the data truncated at 250 mg/dl with the original estimates based on the entire data set. The two nonparametric GAM (2-df) estimates are almost identical in the range of TC values below 200 mg/dl and gradually diverge from each other as they move closer to the cutoff of 250 mg/dl. This illustrates the property of the local dependence of the GAM estimates. The estimated effect of TC below the 250 mg/dl cutoff is only slightly affected by the inclusion in the analysis of individuals with TC values above 250 mg/dl, and this impact is "local," i.e., limited to a rather narrow interval close to the cutoff. The reason why the two GAM estimates are not identical is that GAM smooths the empirical data (15) . When estimating the effect inside a given narrow interval, say TC ranging from 220 to 230 mg/dl, it "borrows strength" from the data in the close neighborhood of that interval. Otherwise, the estimate would be too dependent on few observations that fall in this interval. This would increase the impact of the sampling error, resulting in implausible "bumpy" estimates similar to the 10-df estimates illustrated in figure 1 . The degree of smoothing is controlled by selecting the number of degrees of freedom (15) . It should also be noted that an almost perfect linearity of the 2-df smoothing spline estimate for the truncated data in figure 3 is reassuring in that it confirms that GAM does not "force" nonlinearity in the situations where the data do not require it.
By contrast, the two logistic regression-based estimates in figure 3 differ quite substantially from each other over the entire range of TC from 100 to 250 mg/dl. Indeed, for truncated data, the estimated odds ratio corresponding to an increase of 1 mg/dl is 1.021 (95 percent CI 1.011-1.032), whereas the estimate obtained from the entire data set is 1.010 (95 percent CI 1.004-1.016). This indicates that the estimated relative risk increase resulting from an increase of 1 mg/dl in TC is 2 percent when based on truncated data and 1 percent when based on the entire sample. Thus, inclusion of the individuals with TC above 250 mg/dl results in a twofold decrease of the parametric estimate of the effect of TC in the interval below 250 mg/dl cutoff. Clearly, individuals with TC above the cutoff provide little information about the TC effects in the interval below the cutoff. Therefore, among the two parametric estimates of the TC effects in the lower range, that obtained with data truncated to this range is more accurate. This leads to a conclusion that, when Estimates based on the entire data set are described by linear models (a) and 2-df GAM modeis (b). Estimates based on truncated data are described by linear models (c) and 2-df GAM models (d). All effects are adjusted for risk factors listed in table 1. The relative risks between different risk factor values are accurately represented, but absolute risk levels should not be interpreted. CHD, coronary heart disease.
analyzing the entire data set, formal limitations of the parametric model (in particular, the global dependence of its estimates) result in a biased estimate of the effect of TC even for the interval where the linearity assumption seems to be correct. By contrast, the GAM estimate of the effect of TC below the 250 rng/dl is relatively robust with respect to the inclusion of individuals with values beyond this range so that the GAM estimate obtained using all data is quite similar to the parametric estimate based on truncated data. Table 5 shows the results of testing simultaneously the nonlinearity of the effects of all continuous risk factors in the random sample, each represented by a 2-df smoothing spline. In addition to TC and TC/HDL cholesterol, age also has a significant independent nonlinear effect, while the result is marginally nonsignificant for BMI. By contrast, the linearity assumption appears quite adequate in the case of systolic pressure. Figure 4 compares the GAM estimates (solid curves) with the respective parametric estimates for the five continuous risk factors. All of the GAM estimates, with the exception of TC/HDL cholesterol (see the figure 4 legend for explanation) were obtained simultaneously. Thus, when adjusting the nonparametric effect of a given continuous predictor for the effects of other continuous risk factors, all of these effects are assumed to be represented by the respective (solid) curves in figure 4 rather than by (dotted) lines. The estimates of the effects of TC and TC/HDL cholesterol did not change materially when other risk factors were represented by flexible functions (figure 4) rather than by a straight line (figure 1). This is not surprising given the low correlation between TC and other risk factors. The GAM estimate for systolic pressure confirms linearity of its effect. A marked difference be- tween the parametric and GAM estimates occurs for BMI. The GAM estimate is U-shaped and suggests that the risk of CHD death increases at both extremes of BMI range. By contrast, the parametric estimate is very flat and completely nonsignificant (table 2) . Whereas these results support further the usefuhiess of flexible modeling, we have to interpret the nonlinear effects of age and BMI with some caution since, in contrast to the nonlinear effects of TC, we did not hypothesize such effects a priori.
Simultaneous estimation of nonlinear effects of all continuous risk factors
Model validation
In the validation studies, we have used the subset of individuals who were not taking antihypertensive medications. We had to remove the participants on those medications from the analysis because of the difficulty in separating the effect of the medication and the effect of high systolic pressure in the nonrandom sample, where the two variables were almost collinear (see Parametric logistic regression modeling). This would cause problems in the analyses using the nonrandom sample as the testing sample.
In table 6, the results of validation studies are summarized in terms of the difference in fit to testing sample data between the GAM models and the corresponding parametric multiple logistic models. Using the first validation strategy, we find that the GAM models (estimated from 2,355 medication-free males in the random sample) account slightly worse for the effects of the TC in the nonrandom sample than does the parametric model. By contrast, the GAM models represent the effects of TC/HDL cholesterol in the nonrandom sample substantially better than the parametric model. Thus, we cannot draw firm conclusions about the extent to which the nonparametric effects estimated from the random sample of LRC data are generalizable to a different data set. However, as pointed out in the "Model validation" subsection of the "Statistical analyses" section, the results of this part of our validation study should be interpreted with caution. Indeed, as discussed in the section Parametric logistic regression modeling, individuals in the nonrandom sample appear to have some high-risk characteristics that are not accounted for by the common risk factors included in our multivariable models. Thus, to obtain a more accurate assessment of the generalizability of nonparametric estimates based on the random sample of LRC data, we will need to repeat the validation with a data set that, although collected in a different study, can be considered a representative sample from a population similar to that screened in the LRC study.
The right side of table 6 shows that in the case of cross-validation of the data from the random sample t Participants on antihypertensive medication are excluded. $ Log-likelihood values of GAM models are compared with those of linear logistic models with the same predictors. A positive value means a better fit of GAM, and a negative value means a worse fit the GAM models performed uniformly better than the parametric logistic model. This indicates that the GAM estimates may be more reproducible and may better predict outcomes in "new" cases arising from exactly the same population. The fact that the improvement in the fit offered by GAM is more substantial for TC effects than for TC/HDL cholesterol is consistent with the finding that in the case of TC, nonlinear effects are more apparent and more significant ( figure 1 and table 3) .
Finally, the results in table 6 do not provide conclusive evidence that nonparametric representation of the effects of age and BMI further improve the predictive ability of the GAM models, in comparison with the models in which only the cholesterol effects are modeled by smoothing splines. Replacing parametric estimates of the effects of age and BMI by nonparametric effects further improves the predictive ability of the GAM model in the cross-validation of the random sample data but not in the validation based on the nonrandom sample. Moreover, in all cases, the difference between the two GAM models with respect to goodness of fit to data is minor (difference in loglikelihood of less than 1.0).
Clinical relevance of nonlinear effects
Having established the significance and robustness of the nonlinear effects of cholesterol on the risk of CHD mortality, we now focus on the clinical relevance of the difference between the nonparametric and parametric estimates. The left panel of figure 5 shows how the estimated probability of a CHD death changes as a function of TC for a hypothetical individual with an "average risk profile" (healthy nonsmoker with the mean values of continuous risk factors, as shown in table 1). As expected, the parametric model overestimates the risk in both tails of the TC distribution and underestimates it over the middle range, in comparison with the GAM estimate. (The right panel of figure 5 shows a similar pattern of differences in the case of TC/HDL cholesterol.) Accordingly, the two models differ substantially with respect to the estimated differences in the risk of CHD death between individuals with different TC levels. The magnitude and the direction of this difference depends on the specific TC values being compared.
This phenomenon is illustrated in figure 6 , which compares the two models with respect to the estimated differences in the 12-year probability of a CHD death corresponding to different modifications of lipid levels and different baseline risk profiles. Regardless of the model used and the specific modification considered, the estimated absolute difference increases as we move from an average risk profile A to an elevated-risk profile B and, finally, to a very high-risk, symptomatic individual C. This merely reflects the differences in the absolute risk levels between these hypothetical individuals. Figure 6 also shows that in many cases the differences between the corresponding GAM (G) and logistic regression (L) estimates are important in absolute values (occasionally exceeding 5 percent in the absolute probability of a CHD death) and/or in relative terms (more than twofold differences). Moreover, the sign of the difference between the two types of estimates depends systematically on a specific interval over which the risk factor is presumed to change. In the case of both TC (top panel) and TC/HDL cholesterol (bottom panel), the logistic model underestimates the impact of the changes closer to the middle range of a respective distribution (figure 6, left side), while it seems to overestimate the impact of changes in the upper tail (right side). 
DISCUSSION
Our reanalysis of the LRC data indicates that the effects of both TC and TC/HDL cholesterol on the risk of CHD mortality in men diverge significantly from the linearity assumption that underlies a logistic regression model. The pattern of nonlinearity of lipid measures effects persists regardless of whether other risk factors are modeled parametrically or not and is robust with respect to the exclusion of high-risk individuals. Comparison between the parametric estimates, restricted by the linearity assumption, and flexible nonparametric estimates suggests that the conventional parametric model may induce two types of bias.
First, the parametric model seems to overestimate the effect of the baseline TC among men whose TC levels exceed 250 mg/dl. For those men, the increase in the risk of CHD mortality associated with an increase in TC level, estimated by the unbiased flexible GAM model, is substantially lower than that predicted by the logistic model, and the discrepancy is clinically important. This leveling off of the effect of cholesterol, measured at baseline, on the risk of CHD death may be partly due to the limitations of the data available. It is possible that a fraction of the individuals in whom high levels of lipids were found at the baseline has undergone some cholesterol-lowering interventions in the subsequent years. In that case, the information about their TC at the baseline may be less relevant to assess their average risk level over the 12 years of follow-up, so that the model using the baseline measurement only will overestimate the risks for those individuals. If for a fraction of men with high lipid levels an attempt has been made to lower their TC to an acceptable level, say 220 mg/dl, then the discrepancy between the current and baseline TC levels will increase with the increasing baseline value. This could explain why the strength of the TC effect, as represented by the slope of the nonparametric estimate of the risk function, gradually decreases as TC increases beyond 220 mg/dl. Consistent with this conjecture, Benfante et al. (21) found that among the participants in the Honolulu Heart Program contacted in 1993, after 25 years of follow-up, there were weak correlations between their recent values of risk factors and the corresponding values measured 25 years earlier. In 1993, 11 percent of the participants in that study reported taking cholesterol-lowering medication, and 54 percent were on a special diet. The prevalence of medication and diet were, respectively, 100 and 30 percent higher among men who developed cardiovascular disease during the follow-up and had, on average, a higher baseline cholesterol level than did the subjects in the noncardiovascular group. For assessment of the adequacy of the conjecture that the leveling off of the GAM estimate of the TC effect in the LRC study is related to the pattern of subsequent changes in TC and, if necessary, for elimination of that type of bias by taking into account changes in the cholesterol level in individual patients, the study design should include repeated measurements of cholesterol. In the absence of repeated measurements, we carried out a simple experiment by simulating what the results would be if the follow-up time were shortened. The motivation was that if the leveling off is due to subsequent changes in the TC levels, then the nonlinear effect will be less marked with shorter follow-up time, presumably associated with less important changes. When the follow-up time was artificially shortened to 6 years, the nonlinearity of the effects persisted for both TC and TC/HDL cholesterol (data not shown). This suggests that nonlinearity cannot be accounted by the subsequent changes in cholesterol levels of individual participants.
It is also possible that the decrease in the estimated effect of TC over the upper tail of its distribution is, at least in part, due to measurement errors. In accordance with the well-known phenomenon of "regression to the mean," the highest among observed TC values are likely to be above the "true" value characterizing a given patient over a relevant period of time. In all of the analyses reported above, we used the TC values observed at the second visit because several other risk factors, adjusted for in those analyses, were measured at the second visit only. To assess the importance of the impact of the presumed regression to the mean, we correlated TC values measured at the second visit (used in the analyses above) with the corresponding first visit values, obtained on average 3 months earlier.
The Pearson correlation coefficient was high {p-0.82), and the mean values of TC at the two visits were almost identical (difference = 0.3 mg/dl). However, in the subset of 28 participants with the highest second visit TC values (i.e., values above 306 mg/dl, corresponding to the 99th percentile of the sample distribution), the second visit mean was higher than the first visit mean by as much as 25.3 mg/dl. This is consistent with the regression to the mean presumption. To assess to what extent the nonlinearity of the GAM estimate based on second visit data may be accounted by the regression to the mean, we carried out additional analyses in which we replaced the second visit TC values with the mean of the two visits. The range of TC values among men in the random sample decreased from 353 mg/dl for the second visit data to 277 mg/dl for the mean of the two visits. The leveling off of the GAM 2 df estimate of the effect of the mean of two TC measurements was slightly less marked than in the case of second visit data alone. However, the nonlinear effect remained significant (p -0.05). This indicates that whereas regression to the mean may contribute to the estimated decrease in the effect of TC in the upper tail of the distribution, there remains a significant departure from linearity that cannot be explained by this phenomenon.
In spite of the abundance of epidemiologic data, the detailed quantification of the impact of serum cholesterol on CHD mortality may require further studies. Recently, Law et al. (28) compared the results of a number of large cohort studies, international comparisons, and randomized clinical trials addressing this issue. Whereas the authors conclude that the log-linear model adequately represents the overall effect of serum cholesterol, their comparison indicates some interesting differences both between and within particular categories of studies, and the reasons for these discrepancies are not obvious. Specifically, figure 2 of the article by Law et al. indicates that among 10 large cohort studies, similar in design to the LRC study, a distinct leveling off of the risks in the upper tail of TC distribution has been observed in three studies. In all three studies, the logarithm of risk is a linear function of TC over the interval below approximately 240 mg/dl, but the impact of further increases is minor (28) . Thus, in these three studies the pattern of changes in the risks, along the spectrum of TC values, is quite similar to that estimated in our nonparametric analyses.
The second type of bias induced by conventional parametric models that rely on the linearity assumption concerns the effects of TC in the range between 100 and 220 mg/dl. This may appear somewhat unexpected given that over this range of low-to-moderate values the linearity assumption seems to be correct. In fact, even potentially very flexible GAM models with several degrees of freedom yield the estimates of the effect of TC on the logit of a CHD death that are almost exactly linear below 220 mg/dl (figure 1). In spite of this, the conventional model considerably underestimates the slope of the risk function over this interval. This occurs because the single-slope restriction of the parametric model induces the global dependence of the estimate. The estimated common ("global") slope represents the average of the local slopes that correspond to the effects of the risk factor specific to different intervals within the range of values observed in the sample. If these local effects are quite different, the global slope overestimates the true effect over some intervals and underestimates it over others. In the case of TC effects on CHD mortality, the GAM estimate of the risk function is linear over the lower range but levels off above the 220 mg/dl. As a result, the global slope of the constrained parametric model may considerably underestimate the true slope over the range 100-220 mg/dl. The undesirable implications of the global dependence are illustrated in figure 3 : The estimated parametric effect of TC over the range of values lower than 250 mg/dl changes substantially depending on whether or not participants with TC values above 250 mg/dl are included in the analysis. The fact that GAM estimates are only locally dependent and, therefore, that their dependence on the data from outside the relevant range is minimal represents, in our opinion, a major advantage of nonparametric modeling.
In summary, our results suggest that by imposing restrictive a priori assumptions conventional parametric regression models may provide biased estimates of the effects of serum cholesterol on CHD mortality. Our finding that nonlinear effects are statistically significant, robust, and clinically important raises the possibility of revising the current perception of the role of lipids in CHD. Specifically, the actual effectiveness of some cholesterol-lowering interventions may be substantially different from that predicted based on parametric modeling of epidemiologic data. However, given the potential impact of such a revision on research, health policy, and clinical practice, it is mandatory to replicate our findings with data collected in a different long-term follow-up study of a similar population. In addition, it is important to ensure that the design of such a study permits the separation of the effects of the baseline risk factor values from the effects of their changes during the follow-up.
From the methodological perspective, our study may convey a message of a more general interest. We have proposed a framework for nonparametric modeling of complex disease processes, and our results illustrate potential benefits of such analyses. We believe that a nonparametric regression approach may offer valuable insights in other epidemiologic studies addressing research questions whose importance makes it mandatory to maximize the accuracy of the estimates.
